Chris Long and his wife, Janet, were thrilled when he became the first patient at MUSC Health to receive the Alzheimer’s drug ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Kevin Smith, a resident of Clifton Park, is experiencing the benefits of a recently approved Alzheimer's drug, Leqembi, as he ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 ...

Microsoft co-founder Bill Gates reflects on his father's Alzheimer's battle and expresses optimism about advancements in ...

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...

And other biotech news brought to you by The Readout.

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

Neither Kisunla (donanemab, Eli Lilly & Co. Inc.) or Leqembi (lecanemab, Eisai Co. Ltd.) “demonstrate sufficient benefit to justify their high cost, including the cost of administering them,” the ...

One of two newly approved drugs for Alzheimer’s disease has been submitted for National Health Insurance (NHI) coverage, and ...